Australia's EVE Health Group jumps on snagging regulatory wins

Eve Health

21/07/2025 02:20

** Shares of EVE Health Group EVE.AX rise 6.7% to A$0.032, their biggest intraday pct gain since July 4

** The pharma co satisfies the regulatory requirements to enable prescription access to its Libbo and Dyspro products in Australia

** Company to now proceed with commercial launch earlier than anticipated

** Libbo is an oral soluble film containing tadalafil, while Dyspro is a cannabinoid-based pastille formulation

** YTD, shares down 20%

(Reporting by Nichiket Sunil in Bengaluru)

((Nichiket.Sunil@thomsonreuters.com))